Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The nice thing about the options are the strike prices at $6.25 and $7.
The inflated salary has to come from someplace and my bet is that this someplace is well known to Missling.
I read the poster, and your speculation is so far off the charts that I'm having a difficult time keeping up with your logic.
Need to ask MacFarlane as he is in charge of PR.
Are they still in the trial? Could be part of the 5 dropouts.
Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.
There's a reason as to why Dr. Missling was hired as the CEO - they NEED financing for P2/3, and guess who has the credentials AND CONTACTS to achieve this goal.
There's also a reason as to why he was just given a significant salary increase and millions in options. Let's not forget they've seen much more data (9 months+) than we've seen, and they obviously like what they're seeing, or they wouldn't have rewarded him so well. I can only assume that he was given the significant salary increase and options for a reason, due to his ability to get the additional funding that he's already committed to getting for p2/3. It sounds to me like "things" are progressing as planned. Again, this is just my opinion.
I wouldn't really expect more than what we are seeing right now.
Ha! The "great dr M" doesn't care. He GOT paid!!!
At least the clown admits that he's shorting it at the bottom of this trash piece.
Poster is devastating
Yeah, please check with your broker. I don't trade on margin either, but I believe most online trade accounts are set up as margin accounts by default. I use more than one online broker and all of my accounts were set up as margin accounts by default. If you can sell shares and use the proceeds to buy more shares the same day (i.e. w/out waiting several days for the cash to clear), the odds are you have a margin account. And if so, most brokerages put your shares in a pool that they can lend for shorting. They can't put your shares in the pool or lend them out if your shares are kept in a cash account, or if the certificates are in your name and not the brokers.
Sure thing, Chump. Like I said, "most" but not all brokers can/will lend them if they're in a margin account because technically the shares are viewed as collateral for whenever you use/need margin, therefore if they're not in a margin account, they may be safe - but always best to check with your broker to be sure.
Actually, I am correct. Every broker is different but "most" will loan your shares unless they're in a cash account regardless if you have a GTC on your shares. I spoke to eTrade and they confirmed that I need to have them in a cash account if I want to protect them. If you still have a concern, I would suggest you call your broker. I've seen this discussion a 1000 times on message boards, and the final answer is always the same.
if your shares are at a price "Good till canceled" the shorts can't borrow them
Agree - I believe we're saying the same thing.
Thanks
JBEM doesn't have anything to do with seethruequity - it's been around for a long time.
Still hoping to uplist organically.
I see that we're the #1 read board on ihub today - 41k reads today!
I think you should reconsider. You're clearly very concerned about AVXL, and now's your chance to get out.
For me, I'm LT and have been for well over a year - no plans to jump ship now.
Where has everyone gone? No posts today?
Are you sure that you're on the right stock board?? This is CYDY...
Support broken. No interest. Slow fade back to .60s
Well said!!! Thanks!
Although I may have missed it, I was on the call and don't recall them saying they're having trouble finding patients, and they DEFINITELY didn't say more dilution was coming - they said they couldn't respond to questions about future funding. You're really starting to sound desperate - you must be expecting to this go back up tomorrow.
They extended the timeline by an entire year, having trouble finding patients for the study, more dilution coming, etc.
If smart money is leaving, then why are you still here?
Smart money is exiting rather than holding the bag imo
Looks like we're the most read msg board on ihub this weekend! Should make for an interesting Monday.
Unfortunately, it will also bring out the trolls, and it appears that it's already started.
According to Macfarlane's comment in the NZ article, he said the p2/3 trial will start later this year or early 2017.
p2/3 to start (early 2017 as per australian article)
If you check the charts, you'll see it was $.20 on 3/24/15 and the 52-week high is $14.84 (post-split) - that's a $.20-$3.70 pre-split increase. I know because I bought it in the $.20s thanks to JBEM (thanks again, JBEM!!!)
Yahoo shows AVXL at 1.45 on October 3 2015, to a 14.33 on November 3.
Actually, the pre-split high was ~$3.70 after going to $14.84 following a 1:4 r/s.
I believe 2.50 was the pre split high! That's not bad though,.20 to 2.50!!!!
Can one of the moderators sticky JBEM's DD above in the introduction section? He did an incredible job and it will give potential investors a great overview of what's on the horizon for CYDY.
Thanks
If you think things are bad here and with the bios in general, take a look at AXON. You'll feel much better.
Pfizer? Hmmmm....
The news that Pfizer discontinued their P2 trial for their AD drug in October underscores how AXON is becoming more like a house of cards. In addition to giving smart retail and investors the green light to reinvest their AXON funds in AVXL, it will also make a lot of the shorts reconsider the risk in shorting AVXL. I mean if you were shorting a stock, which do you think now has less risk - AXON or AVXL? And what really makes shorting AVXL a HUGE risk now is that Pfizer wants an AD drug in their pipeline and Anavex is now in the sweet spot and actively searching for a big-pharma for P2/3. Now this is pure speculation, but can you imagine the price of this stock if AVXL issued a PR announcing that we had partnered with Pfizer? I would think that we would be in the triple-digits over night - a scenario that would be much worse than what Shkreli put the shorts through with that other stock. Can you imagine waking up to see that you're -1,000%to -2,000% underwater?
Again, this is just speculation, but having worked in the corporate world for the last 30 years, I'm fairly confident that the execs at Pfizer are looking for a long-term investment. Again this is just speculation, but for the naysayers who think big pharmas will take a wait-and-see approach before investing in Anavex, the race is on and time's running out. Anavex is already looking for a partner, and the cost of a p2/3 trial for a big pharma is pocket change if you compare it to the risk/reward for a successful AD trial. And what's really interesting is that Pfizer kept it secret for several months - not just because they wanted to avoid a drop in their stock price, because that would have happened eventually, but also because they don't want to have to pay a premium while searching for a future acquisition/partnership. I wouldn't want to be shorting or flipping shares at this stage, especially knowing that Pfizer stopped their trial over 3 months ago. The Pfizer announcement is a game changer for Anavex.
Again, this is just my opinion.
I suspect it's also day traders who are buying low in the morning and expect it to rise knowing that we're very close to getting the next update, and then selling off in the afternoon after it's reached the high for the day.
What I'd like to see (but doubt that we will) is that Dr. M includes an update during the webcast, which will give us a quick bump, and then release a full PR after the meeting. Kind of like a 2-stage booster.
Webcast means he can divulge material information...
an extension w/o moving forward to the next trial would be bad.
He could have put out that management and company is not involved in the investigation.
Yeah baby, go down, I love it !
NwwYorkFBI tweeted on Dec 17th that they did not have a seizure warrant.
The problem is that no one took the time to write a properly worded paragraph in the 10q, stating that no one in the company is being investigated.
After interviewing MS, if they believe there's reason to suspect additional fraud or illegal activity, the FBI can confiscate anything they deem appropriate. Nobody knows what they took AFTER his initial arrest.
If Missling is such a finance whiz, why are no reputable institutions buying shares? Baker Bros., etc.